Citius Oncology Stock Forward View - Simple Regression
| CTOR Stock | 0.79 -0.02 -2.47% |
Investor sentiment around Citius Oncology can cause the stock to overshoot or undershoot its fair value for extended periods. This module tracks sentiment signals to identify when that divergence is likely to correct.
As reflected in current metrics, Citius Oncology reflects the relative strength indicator of 0, indicating compressed downside momentum. At these depths, Citius Oncology may be approaching exhaustion on the sell side, though timing a reversal requires additional confirmation.Momentum
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter -0.03 | EPS Estimate Current Year -0.19 | EPS Estimate Next Year 0.39 | Wall Street Target Price 6 | EPS Estimate Current Quarter -0.04 |
The hype perspective for Citius Oncology maps headline activity to recent price response and peer coverage.
The Simple Regression forecasted value of Citius Oncology on the next trading day is expected to be 1.00 with a mean absolute deviation of 0.06 and the sum of the absolute errors of 3.94.Citius Oncology after-hype prediction price | $ 0.79 |
Sentiment metrics here complement forecasting and technical views with analyst and earnings context.
Cross-verify projections for Citius Oncology using Historical Fundamental Analysis of Citius Oncology. The historical series provides projection context.Citius Oncology Additional Predictive Modules
Predictive models for Citius Oncology combine technical indicators with statistical methods to estimate probable price trajectories. Combining multiple forecasting approaches can reduce model-specific bias and improve reliability.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Simple Regression Price Forecast For the 18th of March 2026
Given 90 days horizon, the Simple Regression forecasted value of Citius Oncology on the next trading day is expected to be 1.00 with a mean absolute deviation of 0.06 , mean absolute percentage error of 0.01 , and the sum of the absolute errors of 3.94 .Please note that although there have been many attempts to predict Citius Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Citius Oncology's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Citius Oncology | Citius Oncology Price Prediction | Research Analysis |
Forecasted Value
For the next trading day, Macroaxis evaluates Citius Oncology's predictive range by looking for statistically meaningful downside and upside boundaries. The projected forecast band currently runs from roughly 0.01 on the downside to about 5.93 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Regression forecasting method's relative quality and the estimations of the prediction error of Citius Oncology stock data series using in forecasting. Note that when a statistical model is used to represent Citius Oncology stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 113.1701 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0646 |
| MAPE | Mean absolute percentage error | 0.0614 |
| SAE | Sum of the absolute errors | 3.9428 |
Investors who believe in mean reversion view Citius Oncology's price extremes not as permanent states but as temporary dislocations that create opportunities for disciplined, contrarian capital allocation.
After-Hype Price Density Analysis
The shape of Citius Oncology's price distribution after major news events tends to be skewed, with larger potential moves to the downside than to the upside for established companies like Citius Oncology. This asymmetry is a key input for options pricing and risk management.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
By studying Citius Oncology's historical news reactions, we generate empirical estimates of the price boundaries that follow significant headlines. Citius Oncology's after-hype downside and upside margins for the prediction period are 0.04 and 5.72, respectively. These estimates are most reliable when Citius Oncology's news reaction patterns have been consistent over multiple events.
Current Value
The after-hype framework applied to Citius Oncology assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. Citius Oncology is High at this time.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Citius Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Citius Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Citius Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.48 | 4.93 | 0.00 | 0.06 | 8 Events | 6 Events | In 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.79 | 0.79 | 0.00 |
|
Hype Timeline
Citius Oncology is currently traded for 0.79. The company stock is not elastic to its hype. The average elasticity to hype of competition is -0.06. Citius is estimated not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is estimated to be very small, whereas the daily expected return is currently at -0.48%. %. The volatility of related hype on Citius Oncology is about 3651.85%, with the expected price after the next announcement by competition of 0.73. About 84.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.22. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Oncology recorded a loss per share of 0.31. The company had not issued any dividends in recent years. Given the investment horizon of 90 days the next estimated press release will be in 8 days. Cross-verify projections for Citius Oncology using Historical Fundamental Analysis of Citius Oncology. The historical series provides projection context.Related Hype Analysis
News about regulatory changes, technological disruptions, or macroeconomic shifts can affect Citius Oncology's entire competitive landscape simultaneously. Monitoring peer reactions to such events helps investors anticipate Citius Oncology's likely response.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| SCLX | Scilex Holding | -0.27 | 8 per month | 0.00 | -0.23 | 7.30 | -8.20 | 20.69 | |
| ACTU | Actuate Therapeutics Common | -0.40 | 5 per month | 0.00 | -0.29 | 5.40 | -9.43 | 29.04 | |
| FBRX | Forte Biosciences | 2.56 | 6 per month | 5.70 | 0.10 | 12.11 | -9.14 | 40.19 | |
| SPRO | Spero Therapeutics | 0.08 | 8 per month | 2.02 | 0.08 | 5.22 | -4.04 | 11.18 | |
| APLT | Applied Therapeutics | 0.00 | 9 per month | 0.00 | -0.19 | 10.00 | -15.73 | 83.66 | |
| VOR | Vor Biopharma | -1.54 | 9 per month | 5.49 | 0.09 | 13.80 | -9.16 | 28.43 | |
| MCRB | Seres Therapeutics | -1.82 | 7 per month | 0.00 | -0.12 | 4.80 | -5.64 | 46.80 | |
| FATE | Fate Therapeutics | -0.01 | 8 per month | 4.14 | 0.06 | 7.34 | -7.63 | 22.03 | |
| LNSR | LENSAR Inc | -0.16 | 6 per month | 0.00 | -0.04 | 2.72 | -3.27 | 20.36 | |
| OWLT | Owlet Inc | 0.21 | 9 per month | 0.00 | -0.21 | 6.04 | -11.88 | 44.66 |
Other Forecasting Options for Citius Oncology
Investors at all stages of experience who consider Citius must develop an understanding of Citius Oncology's price dynamics. The noise embedded in Citius Stock price charts can create misleading signals and skew investment decisions.Citius Oncology Related Equities
The following equities are related to Citius Oncology within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing Citius Oncology against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
Citius Oncology Market Strength Events
Market strength indicators applied to Citius Oncology stock give investors a structured view of the security's momentum relative to the overall market. Using these indicators, traders can refine their timing when entering or exiting positions in Citius Oncology.
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.79 | |||
| Day Typical Price | 0.79 | |||
| Price Action Indicator | -0.01 | |||
| Period Momentum Indicator | -0.02 |
Citius Oncology Risk Indicators
Evaluating Citius Oncology's risk indicators is an important step in accurately forecasting its price and assessing the suitability of an investment. Understanding the risk profile of Citius Oncology's allows investors to make more informed decisions about position sizing and risk.
| Mean Deviation | 3.35 | |||
| Standard Deviation | 4.91 | |||
| Variance | 24.07 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Citius Oncology
The amount of media and story coverage tied to Citius Oncology can signal where market attention is concentrating at the moment. This is most useful when investors want to understand why a security is suddenly drawing more public discussion.
Contributor Headline
Latest Perspective From Macroaxis
Citius Oncology Short Properties
Reviewing short-oriented indicators for Citius Oncology is useful because long and short participants often create very different signals for timing and volatility. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 73.3 M | |
| Cash And Short Term Investments | 3.9 M |
Additional Tools for Citius Stock Analysis
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Stocks Directory Find actively traded stocks across global markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |